-
Drugst.One -- A plug-and-play solution for online systems medicine and network-based drug repurposing
Authors:
Andreas Maier,
Michael Hartung,
Mark Abovsky,
Klaudia Adamowicz,
Gary D. Bader,
Sylvie Baier,
David B. Blumenthal,
Jing Chen,
Maria L. Elkjaer,
Carlos Garcia-Hernandez,
Mohamed Helmy,
Markus Hoffmann,
Igor Jurisica,
Max Kotlyar,
Olga Lazareva,
Hagai Levi,
Markus List,
Sebastian Lobentanzer,
Joseph Loscalzo,
Noel Malod-Dognin,
Quirin Manz,
Julian Matschinske,
Miles Mee,
Mhaned Oubounyt,
Alexander R. Pico
, et al. (14 additional authors not shown)
Abstract:
In recent decades, the development of new drugs has become increasingly expensive and inefficient, and the molecular mechanisms of most pharmaceuticals remain poorly understood. In response, computational systems and network medicine tools have emerged to identify potential drug repurposing candidates. However, these tools often require complex installation and lack intuitive visual network mining…
▽ More
In recent decades, the development of new drugs has become increasingly expensive and inefficient, and the molecular mechanisms of most pharmaceuticals remain poorly understood. In response, computational systems and network medicine tools have emerged to identify potential drug repurposing candidates. However, these tools often require complex installation and lack intuitive visual network mining capabilities. To tackle these challenges, we introduce Drugst.One, a platform that assists specialized computational medicine tools in becoming user-friendly, web-based utilities for drug repurposing. With just three lines of code, Drugst.One turns any systems biology software into an interactive web tool for modeling and analyzing complex protein-drug-disease networks. Demonstrating its broad adaptability, Drugst.One has been successfully integrated with 21 computational systems medicine tools. Available at https://drugst.one, Drugst.One has significant potential for streamlining the drug discovery process, allowing researchers to focus on essential aspects of pharmaceutical treatment research.
△ Less
Submitted 4 July, 2023; v1 submitted 24 May, 2023;
originally announced May 2023.
-
Flimma: a federated and privacy-preserving tool for differential gene expression analysis
Authors:
Olga Zolotareva,
Reza Nasirigerdeh,
Julian Matschinske,
Reihaneh Torkzadehmahani,
Tobias Frisch,
Julian Späth,
David B. Blumenthal,
Amir Abbasinejad,
Paolo Tieri,
Nina K. Wenke,
Markus List,
Jan Baumbach
Abstract:
Aggregating transcriptomics data across hospitals can increase sensitivity and robustness of differential expression analyses, yielding deeper clinical insights. As data exchange is often restricted by privacy legislation, meta-analyses are frequently employed to pool local results. However, if class labels are inhomogeneously distributed between cohorts, their accuracy may drop. Flimma (https://e…
▽ More
Aggregating transcriptomics data across hospitals can increase sensitivity and robustness of differential expression analyses, yielding deeper clinical insights. As data exchange is often restricted by privacy legislation, meta-analyses are frequently employed to pool local results. However, if class labels are inhomogeneously distributed between cohorts, their accuracy may drop. Flimma (https://exbio.wzw.tum.de/flimma/) addresses this issue by implementing the state-of-the-art workflow limma voom in a privacy-preserving manner, i.e. patient data never leaves its source site. Flimma results are identical to those generated by limma voom on combined datasets even in imbalanced scenarios where meta-analysis approaches fail.
△ Less
Submitted 23 November, 2020; v1 submitted 30 October, 2020;
originally announced October 2020.
-
Exploring the SARS-CoV-2 virus-host-drug interactome for drug repurposing
Authors:
Sepideh Sadegh,
Julian Matschinske,
David B. Blumenthal,
Gihanna Galindez,
Tim Kacprowski,
Markus List,
Reza Nasirigerdeh,
Mhaned Oubounyt,
Andreas Pichlmair,
Tim Daniel Rose,
Marisol Salgado-Albarrán,
Julian Späth,
Alexey Stukalov,
Nina K. Wenke,
Kevin Yuan,
Josch K. Pauling,
Jan Baumbach
Abstract:
Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. It was first identified in Wuhan, China, and has since spread causing a global pandemic. Various studies have been performed to understand the molecular mechanisms of viral infection for predicting drug repurposing candidates. However, such information is spread across many publications and it is very time…
▽ More
Coronavirus Disease-2019 (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus. It was first identified in Wuhan, China, and has since spread causing a global pandemic. Various studies have been performed to understand the molecular mechanisms of viral infection for predicting drug repurposing candidates. However, such information is spread across many publications and it is very time-consuming to access, integrate, explore, and exploit. We developed CoVex, the first interactive online platform for SARS-CoV-2 and SARS-CoV-1 host interactome exploration and drug (target) identification. CoVex integrates 1) experimentally validated virus-human protein interactions, 2) human protein-protein interactions and 3) drug-target interactions. The web interface allows user-friendly visual exploration of the virus-host interactome and implements systems medicine algorithms for network-based prediction of drugs. Thus, CoVex is an important resource, not only to understand the molecular mechanisms involved in SARS-CoV-2 and SARS-CoV-1 pathogenicity, but also in clinical research for the identification and prioritization of candidate therapeutics. We apply CoVex to investigate recent hypotheses on a systems biology level and to systematically explore the molecular mechanisms driving the virus life cycle. Furthermore, we extract and discuss drug repurposing candidates involved in these mechanisms. CoVex renders COVID-19 drug research systems-medicine-ready by giving the scientific community direct access to network medicine algorithms integrating virus-host-drug interactions. It is available at https://exbio.wzw.tum.de/covex/.
△ Less
Submitted 26 April, 2020;
originally announced April 2020.
